ROSEVILLE, Calif.--(BUSINESS WIRE)--Dutton Associates initiates coverage of Linkwell Corporation
(OTCBB:
LWLL -
News) with a Strong Speculative Buy rating and a price target of
$.38. The 13-page report by Dutton senior analyst Stanley Ng is
available at
www.jmdutton.com
as well as from First Call, Bloomberg Professional, Zacks, Reuters,
Knobias, JCF Group and other leading financial portals.
Linkwell is principally engaged in the development, manufacture, sale
and distribution of disinfectant healthcare products, primarily to the
medical industry in China. The Company has a nationwide marketing and
sales presence throughout all 22 provinces, as well as four autonomous
regions and five municipalities in China. This provides Linkwell a major
competitive edge over the much larger foreign competitors like 3M and
Johnson & Johnson, due to their limited product line and inability to
attain critical mass in the China disinfectant market. Cooperation
agreements with Ecolab signed in mid-February indicate that even the
global leader in the healthcare and disinfectant industry wishes to
leverage on Linkwell¡¯s established marketing
channels to grow its business in the huge China disinfectant market. In
our view, Linkwell is an attractive vehicle to participate in China¡¯s
large and growing disinfectant market, which is driven by increasing
health consciousness in China, ongoing government reforms in hospital
sanitation, medical standards and disinfectant regulations and the
government¡¯s educational program to increase
awareness about public health and hygienic standards. One of Linkwell¡¯s
major products, An¡¯erdian Skin Disinfectant,
has been chosen for use in all hospitals supporting the 2008 Beijing
Olympic Games. Also, Linkwell has been selected to train and license all
disinfectant and pest control professionals in China for the Beijing
Olympics.
About Dutton Associates
Dutton Associates is one of the largest independent investment research
firms in the U.S. Its 30 senior analysts are primarily CFAs, and have
expertise in many industries. Dutton Associates provides continuing
analyst coverage of over 140 enrolled companies, and its research,
estimates, and ratings are carried in all the major databases serving
institutions and online investors.
The cost of enrollment in our one-year continuing research program is US
$35,000 prepaid for 4 Research Reports, typically published quarterly,
and requisite Research Notes. The Firm does not accept any equity
compensation. We received $20,000 from the Company for 2 Research
Reports commencing on 05/09/2008. Our principals and analysts are
prohibited from owning or trading in securities of covered companies.
The views expressed in this research report accurately reflect the
analyst's personal views about the subject securities or issuer. Neither
the analyst's compensation nor the compensation received by us is in any
way related to the specific ratings or views contained in this research
report or note. Please read full disclosures and analyst background at www.jmdutton.com
before investing.
